Ertugliflozin offers some kidney protection

Despite earlier reports that the sodium-glucose transport protein 2 (SGLT2) inhibitor ertugliflozin did not live up to expectations for kidney disease outcomes, an analysis by Prof. David Cherney (University of Toronto, Canada) provides evidence that kidney disease outcomes with ertugliflozin were similar to those seen with other SGLT2 inhibitors. The VERTIS CV study (NCT01986881) compared the SGLT2 inhibitor ertugliflozin (n=5,499) with placebo (n=2,747). The primary endpoint was a composite of kidney outcomes, including renal death, need for dialysis or transplant, or a doubling of serum creatinine reflecting a drop of at least 50% in estimated glomerular filtration rate (eGFR). Although the composite outcome showed a trend towards significant benefit, there was only a nominal 19% reduction of primary outcome events with ertugliflozin (HR 0.81; 95.8% C...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 14 December, 202017 December, 2020